Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 4/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.52 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | PRKX | P51817 | 3/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.46 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.46 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.45 |
| ▸ | CDK8 | P49336 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16667689 | 1.00 | CLK2 (0.52) | CLK2CLK4MAP4K4DYRK1ASRPK1 | |
| SCHEMBL9924150 | 0.71 | LMNA (0.45) | ALDH1A1MEN1KMT2ATHRBNPC1 | |
| SCHEMBL16675917 | 0.71 | NPY5R (0.43) | CLK4MAP4K4PDGFRBAURKBAURKA | |
| SCHEMBL16675943 | 0.71 | GRM4 (0.40) | AURKANTRK1CYP1A2CYP2D6RPS6KB1 | |
| SCHEMBL16675911 | 0.70 | NPC1 (0.39) | MAP4K4ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL16682180 | 0.70 | CYP2D6 (0.51) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL18556887 | 0.69 | CYP2D6 (0.48) | AURKBAURKAROCK2CYP2D6RPS6KB1 | |
| SCHEMBL16675939 | 0.69 | CDK2 (0.39) | CLK2CLK4MAP4K4DYRK1ASRPK1 | |
| SCHEMBL28573658 | 0.68 | MAOB (0.73) | CLK2CLK4MAP4K4DYRK1ASRPK1 | |
| SCHEMBL13122036 | 0.67 | INSR (0.67) | CLK2CLK4MAP4K4DYRK1ASRPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | CLK2 4179/4885CLK4 4343/4885MAP4K4 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.